Cannabinoid Formulation for Pain Management

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pain management options, such as opioid drugs, often come with undesirable side effects like stomach upset, constipation, and risk of addiction, highlighting the need for effective and safer alternatives.

Innovation Solution

A cannabinoid formulation comprising tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) in specific ratios (30%-45% THC, 9%-35% CBC, and 30%-45% CBD) is administered to manage pain associated with musculoskeletal, osteoarthritis, and inflammatory conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If opioid drugs are used for pain management, then pain relief is achieved, but side effects such as stomach upset, constipation, and risk of addiction occur

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidside effects and addiction risk

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical composition parameters by using cannabinoid compounds (THC, CBD, CBC) instead of opioid substances, fundamentally altering the pharmacological profile to achieve pain relief without opioid-related side effects and addiction risk

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite formulation containing multiple cannabinoid compounds (THC, CBD, and CBC) in specific ratios, leveraging their synergistic effects to enhance pain management while minimizing individual compound side effects

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If cannabinoid formulations are used as alternatives to opioids, then side effects are minimized, but the effectiveness and dosage optimization need to be established

Engineering Contradiction:

Improveside effectsVSAvoiddosage optimization and effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSQuantity of substance

Solution Approach 1:

The patent optimizes the concentration parameters of individual cannabinoid compounds (THC: 1-20mg, CBD: 1-20mg, CBC: 1-10mg per dose) to achieve effective pain management while maintaining safety and minimizing side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent assigns different functional roles to each cannabinoid compound based on their specific pharmacological properties: THC for analgesia, CBD for anti-inflammatory effects and anxiety reduction, and CBC for additional pain relief, creating a balanced formulation where each component contributes optimally to the overall therapeutic effect

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation effectively reduces pain intensity and improves mobility in subjects with neuropathic pain, offering a safer alternative to opioids by minimizing side effects and potentially reducing the daily dose required for pain management.

Implementation Method 1

Cannabinoids are a group of structurally similar compounds isolated from cannabis plants, which activate cannabinoid receptors and ion channels in cells

Methodology Applied

Scientific EffectCannabinoid receptor activation:

Implementation Method 2

Cannabinoids are a group of structurally similar compounds isolated from cannabis plants, which activate cannabinoid receptors and ion channels in cells

Methodology Applied

Scientific EffectIon channel activation:

Implementation Method 3

CBD is regarded as having an effect on 5HT1A receptor-mediated neurotransmission

Methodology Applied

Scientific EffectReceptor-mediated neurotransmission:

Implementation Method 4

CBC has moderate affinity (Ki ~100 nanomolar) only for CB2 receptors and binds to CB1 receptors only at concentrations higher than 1 micromolar

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 5

CBC is found to be the most potent agonist of all the phytocannabinoids at TRPA1 channels

Methodology Applied

Scientific EffectTRPA1 channel activation:

Implementation Method 6

Δ9-THC exerts partial agonistic activity on CB1 and CB2 receptors with high binding affinity with CB1 receptor leading to its psychoactive activity

Methodology Applied

Scientific EffectPartial agonistic activity:

Data Source

PatentUS12220396B2Formulation for pain management

Publication Date: 2025.02.11 ZYUS LIFE SCI INC

AI summary

A method of pain management is described, for use by individuals experiencing pain from musculoskeletal pain, osteoarthritis, and/or joint pain, including pain attributable to inflammation, comprising administration of a formulation comprising a plurality of cannabinoids. Primary cannabinoids are present in the formulation in amounts according to a weight ratio of THC:CBC:CBD ranging from 5:5:5 to 5:1:5. Methods of using the formulation, doses and dosage forms are described, including a formulation pairing in which a first formulation comprising CBC:CBD at 1:5 to 5:5 is utilized at certain times of day when psychoactive effects of THC are not desired, and a second formulation comprising THC:CBC:CBD is used at other times of day, typically evening or bedtime.